Immunotherapy of leukemia and lymphoma

S. Murphy, E. Hersh

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Clinical trials in leukemia and lymphoma have provided suggestive evidence that immunotherapy contributes to the overall management of these neoplasms. Not all disease categories nor every patient within a category has benefited from the specific immunotherapy they have received. In fact, there is certain evidence that overstimulation as well as inadequate stimulation may be harmful. Advances in knowledge of the biologic importance of general and specific immunocompetence should lead to a more rational use of immunotherapeutic agents.

Original languageEnglish (US)
Pages (from-to)181-203
Number of pages23
JournalSeminars in hematology
Volume15
Issue number2
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Immunotherapy of leukemia and lymphoma'. Together they form a unique fingerprint.

  • Cite this